1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
2
|
Lozano R, Naghavi M, Foreman K, Lim S,
Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY, et
al: Global and regional mortality from 235 causes of death for 20
age groups in 1990 and 2010: A systematic analysis for the Global
Burden of Disease Study 2010. Lancet. 380:2095–2128. 2012.
View Article : Google Scholar : PubMed/NCBI
|
3
|
Zhang C, Chen X, Li L, Zhou Y, Wang C and
Hou S: The Association between telomere length and cancer
prognosis: Evidence from a meta-analysis. PLoS One.
10:e01331742015. View Article : Google Scholar : PubMed/NCBI
|
4
|
Ito S, Ohga T, Saeki H, Nakamura T,
Watanabe M, Tanaka S, Kakeji Y and Maehara Y: p53 mutation
profiling of multiple esophageal carcinoma using laser capture
microdissection to demonstrate field carcinogenesis. Int J Cancer.
113:22–28. 2005. View Article : Google Scholar : PubMed/NCBI
|
5
|
Kuwano H, Kato H, Miyazaki T, Fukuchi M,
Masuda N, Nakajima M, Fukai Y, Sohda M, Kimura H and Faried A:
Genetic alterations in esophageal cancer. Surg Today. 35:7–18.
2005. View Article : Google Scholar : PubMed/NCBI
|
6
|
Karahoca M and Momparler RL:
Pharmacokinetic and pharmacodynamic analysis of
5-aza-2′-deoxycytidine (decitabine) in the design of its
dose-schedule for cancer therapy. Clin Epigenetics. 5:32013.
View Article : Google Scholar : PubMed/NCBI
|
7
|
Singh V, Sharma P and Capalash N: DNA
methyltransferase-1 inhibitors as epigenetic therapy for cancer.
Curr Cancer Drug Targets. 13:379–399. 2013. View Article : Google Scholar : PubMed/NCBI
|
8
|
Borges S, Döppler H, Perez EA, Andorfer
CA, Sun Z, Anastasiadis PZ, Thompson E, Geiger XJ and Storz P:
Pharmacologic reversion of epigenetic silencing of the PRKD1
promoter blocks breast tumor cell invasion and metastasis. Breast
Cancer Res. 15:R662013. View
Article : Google Scholar : PubMed/NCBI
|
9
|
Karpf AR, Moore BC, Ririe TO and Jones DA:
Activation of the p53 DNA damage response pathway after inhibition
of DNA methyltransferase by 5-aza-2′-deoxycytidine. Mol Pharmacol.
59:751–757. 2001. View Article : Google Scholar : PubMed/NCBI
|
10
|
Eiseler T, Döppler H, Yan IK, Goodison S
and Storz P: Protein kinase D1 regulates matrix metalloproteinase
expression and inhibits breast cancer cell invasion. Breast Cancer
Res. 11:R132009. View
Article : Google Scholar : PubMed/NCBI
|
11
|
Jüttermann R, Li E and Jaenisch R:
Toxicity of 5-aza-2′-deoxycytidine to mammalian cells is mediated
primarily by covalent trapping of DNA methyltransferase rather than
DNA demethylation. Proc Natl Acad Sci USA. 91:pp. 11797–11801.
1994; View Article : Google Scholar : PubMed/NCBI
|
12
|
Brueckner B, Garcia Boy R, Siedlecki P,
Musch T, Kliem HC, Zielenkiewicz P, Suhai S, Wiessler M and Lyko F:
Epigenetic reactivation of tumor suppressor genes by a novel
small-molecule inhibitor of human DNA methyltransferases. Cancer
Res. 65:6305–6311. 2005. View Article : Google Scholar : PubMed/NCBI
|
13
|
Bardenheuer W, Lehmberg K, Rattmann I,
Brueckner A, Schneider A, Sorg UR, Seeber S, Moritz T and Flasshove
M: Resistance to cytarabine and gemcitabine and in vitro selection
of transduced cells after retroviral expression of cytidine
deaminase in human hematopoietic progenitor cells. Leukemia.
19:2281–2288. 2005. View Article : Google Scholar : PubMed/NCBI
|
14
|
Wang Z, Hou J, Lu L, Qi Z, Sun J, Gao W,
Meng J, Wang Y, Sun H, Gu H, et al: Small ribosomal protein subunit
S7 suppresses ovarian tumorigenesis through regulation of the
PI3K/AKT and MAPK pathways. PLoS One. 8:e791172013. View Article : Google Scholar : PubMed/NCBI
|
15
|
Shridhar R, Almhanna K, Meredith KL,
Biagioli MC, Chuong MD, Cruz A and Hoffe SE: Radiation therapy and
esophageal cancer. Cancer Contr. 20:97–110. 2013. View Article : Google Scholar
|
16
|
Jones PA and Baylin SB: The epigenomics of
cancer. Cell. 128:683–692. 2007. View Article : Google Scholar : PubMed/NCBI
|
17
|
Hoque MO, Rosenbaum E, Westra WH, Xing M,
Ladenson P, Zeiger MA, Sidransky D and Umbricht CB: Quantitative
assessment of promoter methylation profiles in thyroid neoplasms. J
Clin Endocrinol Metab. 90:4011–4018. 2005. View Article : Google Scholar : PubMed/NCBI
|
18
|
Miyamoto K, Fukutomi T, Akashi-Tanaka S,
Hasegawa T, Asahara T, Sugimura T and Ushijima T: Identification of
20 genes aberrantly methylated in human breast cancers. Int J
Cancer. 116:407–414. 2005. View Article : Google Scholar : PubMed/NCBI
|
19
|
McKie AB, Douglas DA, Olijslagers S,
Graham J, Omar MM, Heer R, Gnanapragasam VJ, Robson CN and Leung
HY: Epigenetic inactivation of the human sprouty2 (hSPRY2)
homologue in prostate cancer. Oncogene. 24:2166–2174. 2005.
View Article : Google Scholar : PubMed/NCBI
|
20
|
An C, Choi IS, Yao JC, Worah S, Xie K,
Mansfield PF, Ajani JA, Rashid A, Hamilton SR and Wu TT: Prognostic
significance of CpG island methylator phenotype and microsatellite
instability in gastric carcinoma. Clin Cancer Res. 11:656–663.
2005.PubMed/NCBI
|
21
|
Feinberg AP, Cui H and Ohlsson R: DNA
methylation and genomic imprinting: Insights from cancer into
epigenetic mechanisms. Semin Cancer Biol. 12:389–398. 2002.
View Article : Google Scholar : PubMed/NCBI
|
22
|
Egger G, Liang G, Aparicio A and Jones PA:
Epigenetics in human disease and prospects for epigenetic therapy.
Nature. 429:457–463. 2004. View Article : Google Scholar : PubMed/NCBI
|
23
|
Abdulhaq H and Rossetti JM: The role of
azacitidine in the treatment of myelodysplastic syndromes. Expert
Opin Investig Drugs. 16:1967–1975. 2007. View Article : Google Scholar : PubMed/NCBI
|
24
|
Luo J, Wang W, Tang Y, Zhou D, Gao Y,
Zhang Q, Zhou X, Zhu H, Xing L and Yu J: mRNA and methylation
profiling of radioresistant esophageal cancer cells: The
involvement of Sall2 in acquired aggressive phenotypes. J Cancer.
8:646–656. 2017. View Article : Google Scholar : PubMed/NCBI
|
25
|
Stresemann C, Brueckner B, Musch T,
Stopper H and Lyko F: Functional diversity of DNA methyltransferase
inhibitors in human cancer cell lines. Cancer Res. 66:2794–2800.
2006. View Article : Google Scholar : PubMed/NCBI
|
26
|
Yang H, Tian ST, Wu RY, Chen Y, Mei ZN,
Wang CY and Yang GZ: Glycoborinine induces apoptosis through
mitochondrial pathway in HepG2 cells. J Asian Nat Prod Res.
16:991–999. 2014. View Article : Google Scholar : PubMed/NCBI
|
27
|
Wimardhani YS, Suniarti DF, Freisleben HJ,
Wanandi SI, Siregar NC and Ikeda MA: Chitosan exerts anticancer
activity through induction of apoptosis and cell cycle arrest in
oral cancer cells. J Oral Sci. 56:119–126. 2014. View Article : Google Scholar : PubMed/NCBI
|
28
|
Oh KJ, Barbuto S, Pitter K, Morash J,
Walensky LD and Korsmeyer SJ: A membrane-targeted BID BCL-2
homology 3 peptide is sufficient for high potency activation of BAX
in vitro. J Biol Chem. 281:36999–37008. 2006. View Article : Google Scholar : PubMed/NCBI
|
29
|
He J, Li J, Ye C, Zhou L, Zhu J, Wang J,
Mizota A, Furusawa Y and Zhou G: Cell cycle suspension: A novel
process lurking in G2 arrest. Cell Cycle. 10:1468–1476.
2011. View Article : Google Scholar : PubMed/NCBI
|
30
|
Zheng R, Liu Y, Zhang X, Zhao P and Deng
Q: miRNA-200c enhances radiosensitivity of esophageal cancer by
cell cycle arrest and targeting P21. Biomed Pharmacother.
90:517–523. 2017. View Article : Google Scholar : PubMed/NCBI
|
31
|
Liu J, Shen W, Tang Y, Zhou J, Li M, Zhu
W, Yang H, Wu J, Zhang S and Cao J: Proteasome inhibitor MG132
enhances the antigrowth and antimetastasis effects of radiation in
human nonsmall cell lung cancer cells. Tumour Biol. 35:7531–7539.
2014. View Article : Google Scholar : PubMed/NCBI
|
32
|
Xu D, Yang F, He H, Hu J, Lv X, Ma D and
Chen YY: Expression of TMEM166 protein in human normal and tumor
tissues. Appl Immunohistochem Mol Morphol. 21:543–552. 2013.
View Article : Google Scholar : PubMed/NCBI
|
33
|
Sun W, Ma XM, Bai JP, Zhang GQ, Zhu YJ, Ma
HM, Guo H, Chen YY and Ding JB: Transmembrane protein 166
expression in esophageal squamous cell carcinoma in Xinjiang,
China. Asian Pac J Cancer Prev. 13:3713–3716. 2012. View Article : Google Scholar : PubMed/NCBI
|